MeiraGTx’s Phase II Gene Therapy For Parkinson’s Shows Efficacy, Safety

 
• By Joseph Haas

Although the data are from a small bridging study, MeiraGTx plans to discuss Phase III options for AAV-GAD in Parkinson’s disease after showing efficacy on a disease rating scale and a quality-of-life measure.

MeiraGTx has high hopes for its Parkinson's disease gene therapy candidate (Shutterstock)

More from Neurological

More from R&D